Floatz logo

Methylphenidate

Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2)

University Hospital, ToursSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

574 Active assets in the Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2) cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB

View all 50 →

Same molecule, other indications

Methylphenidate is also rated in:

attention deficit-hyperactivity disorderDormant
BBB
Indicative ·
76 / 100
View asset →
ApathyDormant
BBB
Indicative ·
72 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →